Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.

In this study, we report an unexpected favorable response to etoposide and cisplatin (EP) from an EGFR-mutant patient who developed SCLC transformation at disease progression after the administration of erlotinib with a progression-free survivalof 7.7 months. At disease progression (PD) after erlotinib, rebiopsy showed typical SCLC histology accompanied by positive expressions of CD56, TTF-1, CK7, and synaptophysin. Subsequently, he was switched to standard SCLC treatment regimen EP in combination with erlotinib due to the retention of EGFR 19 del and achieved PR four cycles after the treatment. His disease progressed again 7.7 months after the initiation of EP treatment, with an enlargement of both primary and metastatic lesions. Collectively, this case illustrated the transformation from adenocarcinoma to SCLC and the subsequent durable benefit from standard treatment for SCLC. PMID: 31161851 [PubMed - as supplied by publisher]
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research

Related Links:

Conclusions: Intrapatient molecular or histologic heterogeneity may be frequently found during routine treatment of non–small cell lung cancer patients. This biological aspect may have profound repercussions on subsequent therapeutic decisions, and therefore requires in-depth investigation.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Thoracic Source Type: research
Conclusion Gefitinib, erlotinib, and afatinib have similar effectiveness in advanced stage N SCLC with EGFR mutation positive. Afatinib tends to be associated with longer PFS but further investigation is required. DOI: 10.3779/j.issn.1009-3419.2019.09.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
enkins Lung cancer is the leading cause of cancer-related mortality, which histologically is classified into small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of all lung cancer diagnoses, with the majority of patients presenting with lung adenocarcinoma (LAC). KRAS mutations are a major driver of LAC, and are closely related to cigarette smoking, unlike mutations in the epidermal growth factor receptor (EGFR) which arise in never-smokers. Although the past two decades have seen fundamental progress in the treatment and diagnosis of NSCLC, NSCLC still is predomin...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Lung cancer is the most common cause of cancer-related death worldwide. There are two classes of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC represents approximately 85% of all lung cancer cases. Immune checkpoint inhibitors (ICIPs) are a class of inhibitors of programmed death-1 and programmed death-ligand 1. Preclinical studies have shown that ICIPs have shown good clinical efficacy and durable response in diverse cancers. Among them, atezolizumab (MPDL3280), an anti-PD-L1 monoclonal antibody, is being investigated as a potential therapy against solid tumors and hematologic ma...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Conclusions: This study concludes that 68Ga Pentixafor is a promising future PET molecule for imaging CXCR4 over expression reported in lung cancer and many other human malignancies. This novel PET tracer has the potential of becoming a powerful tool for monitoring therapy response to CXCR4 inhibitors and also for the development of emerging alpha/beta targeted therapies in advanced stage lung carcinoma. $$graphic_078CAB3A-2C78-49E0-8A2E-0F11F0BF0518$$
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer I: Molecular Biomarkers and Molecular Imaging Signatures Source Type: research
CONCLUSION: To our knowledge this is the first study comparing the levels of protein and mRNA in the serum material of HGF, c-MET, EGF and EGFR parameters in lung cancer patients' blood samples. Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies. PMID: 31104010 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Lung cancer is the leading cause of cancer related mortality globally and is classified as either Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC) upon pathology review. [1,2] The main histologic types of NSCLC include squamous cell carcinoma and adenocarcinoma. [2] The majority of patients have non-curable disease stage at the time of diagnosis. Advances in systemic treatments including chemotherapy, targeted therapies and immune check point inhibitors have improved prognosis in recent years.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: May 2019Source: Journal of the American College of Radiology, Volume 16, Issue 5, SupplementAuthor(s): Expert Panel on Thoracic Imaging:, Patricia M. de Groot, Jonathan H. Chung, Jeanne B. Ackman, Mark F. Berry, Brett W. Carter, Patrick M. Colletti, Stephen B. Hobbs, Barbara L. McComb, Benjamin Movsas, Betty C. Tong, Christopher M. Walker, Sue S. Yom, Jeffrey P. KanneAbstractLung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but oth...
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
Lung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but other significant risk factors include exposure to secondhand smoke, environmental radon, occupational exposures, and air pollution. Education and socioeconomic status affect both incidence and outcomes. Non –small-cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, comprises about 85% of lung cancers.
Source: Journal of the American College of Radiology : JACR - Category: Radiology Authors: Tags: Appropriate use criteria Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Biology | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Small Cell Lung Cancer | Study | Tarceva